Desmond G. Johnston

Desmond G. Johnston

Auto-generated profile, based on publicly available information

Desmond G. Johnston

Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EGEdward W. Gregg
Edward W. Gregg
APAdrian Pratt
Adrian Pratt
AOAlex Owens
Alex Owens
EBEmma Barron
Emma Barron
RDRupert Dunbar-Rees
Rupert Dunbar-Rees
JVJonathan Valabhji
Jonathan Valabhji
Diabetes mellitus is a central driver of multiple long-term conditions (MLTCs), but population-based studies have not clearly characterized the burden across the life course. We estimated the age of onset, years of life spent and loss associated with diabetes-related MLTCs among 46 million English adults. We found that morbidity patterns extend beyond classic diabetes complications and accelerate the onset of severe MLTCs by 20 years earlier in life in women and 15 years earlier in men. By the age of 50 years, one-third of those with diabetes have at least three conditions, spend >20 years with them and die 11 years earlier than the general population. Each additional condition at the age of 50 years is associated with four fewer years of life. Hypertension, depression, cancer and coronary heart disease contribute heavily to MLTCs in older age and create the greatest community-level burden on years spent (813 to 3,908 years per 1,000 individuals) and lost (900 to 1,417 years per 1,000 individuals). However, in younger adulthood, depression, severe mental illness, learning disabilities, alcohol dependence and asthma have larger roles, and when they occur, all except alcohol dependence were associated with long periods of life spent (11–14 years) and all except asthma associated with many years of life lost (11–15 years). These findings provide a baseline for population monitoring and underscore the need to prioritize effective prevention and management approaches.

4 April 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
VBVassiliki Bravis
Vassiliki Bravis
AKAkaal Kaur
Akaal Kaur
HWHelen C Walkey
Helen C Walkey
IGIan F Godsland
Ian F Godsland
SMShivani Misra
Shivani Misra
DJDesmond G Johnston
Desmond G Johnston
Objectives: To describe the characteristics of children and adults with incident type 1 diabetes in contemporary, multiethnic UK, focusing on differences between the islet autoantibody negative and positive. Design: Observational cohort study. Setting: 146 mainly secondary care centres across England and Wales. Participants: 3312 people aged ≥5 years were recruited within 6 months of a clinical diagnosis of type 1 diabetes via the National Institute for Health Research Clinical Research Network. 3021 were of white European ethnicity and 291 (9%) were non-white. There was a small male predominance (57%). Young people <17 years comprised 59%. Main outcome measures: Autoantibody status and characteristics at presentation. Results: The majority presented with classical osmotic symptoms, weight loss and fatigue. Ketoacidosis was common (42%), especially in adults, and irrespective of ethnicity. 35% were overweight or obese. Of the 1778 participants who donated a blood sample, 85% were positive for one or more autoantibodies against glutamate decarboxylase, islet antigen-2 and zinc transporter 8. Presenting symptoms were similar in the autoantibody-positive and autoantibody-negative participants, as was the frequency of ketoacidosis (43%vs40%, P=0.3). Autoantibody positivity was less common with increasing age (P=0.0001), in males compared with females (82%vs90%, P<0.0001) and in people of non-white compared with white ethnicity (73%vs86%, P<0.0001). Body mass index was higher in autoantibody-negative adults than autoantibody-positive adults (median, IQR 25.5, 23.1–29.2vs23.9, 21.4–26.7 kg/m2; P=0.0001). Autoantibody-negative participants were more likely to have a parent with diabetes (28%vs16%, P<0.0001) and less likely to have another autoimmune disease (4%vs8%, P=0.01). Conclusions: Most people assigned a diagnosis of type 1 diabetes presented with classical clinical features and islet autoantibodies. Although indistinguishable at an individual level, autoantibody-negative participants as a group demonstrated features more typically associated with other diabetes subtypes. Trial registration number: ISRCTN66496918; Pre-results.

1 December 2016 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
AEAhmed H. El-Laboudi
Ahmed H. El-Laboudi
IGIan F. Godsland
Ian F. Godsland
DJDesmond G. Johnston
Desmond G. Johnston
NONicholas Oliver
Nicholas Oliver
Objective: To report the impact of continuous glucose monitoring (CGM) on glycemic variability (GV) indices, factors predictive of change, and to correlate variability with conventional markers of glycemia. Methods: Data from the JDRF study of CGM in participants with type 1 diabetes were used. Participants were randomized to CGM or self-monitored blood glucose (SMBG). GV indices at baseline, at 26 weeks in both groups, and at 52 weeks in the control group were analyzed. The associations of demographic and clinical factors with change in GV indices from baseline to 26 weeks were evaluated. Results: Baseline data were available for 448 subjects. GV indices were all outside normative ranges ( P < 0.001). Intercorrelation between GV indices was common and, apart from coefficient of variation (CV), low blood glucose index (LBGI), and percentage of glycemic risk assessment diabetes equation score attributable to hypoglycemia (%GRADE hypoglycemia ), all indices correlate positively with HbA1c. There was strong correlation between time spent in hypoglycemia, and CV, LBGI, and %GRADE hypoglycemia , but not with HbA1c. A significant reduction in all GV indices, except lability index and mean absolute glucose change per unit time (MAG), was demonstrated in the intervention group at 26 weeks compared with the control group. Baseline factors predicting a change in GV with CGM include baseline HbA1c, baseline GV, frequency of daily SMBG, and insulin pump use. Conclusions: CGM reduces most GV indices compared with SMBG in people with type 1 diabetes. The strong correlation between time spent in hypoglycemia and CV, LBGI, and %GRADE hypoglycemia highlights the value of these metrics in assessing hypoglycemia as an adjunct to HbA1c in the overall assessment of glycemia.

9 January 2020 in Diabetologia
Verified
Journal Article
Open access
PDF file
ANArun Nanditha
Arun Nanditha
HTHazel Thomson
Hazel Thomson
PSPriscilla Susairaj
Priscilla Susairaj
WSWeerachai Srivanichakorn
Weerachai Srivanichakorn
NONick Oliver
Nick Oliver
ARAmbady Ramachandran
Ambady Ramachandran
Aims/hypothesis: This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications, to prevent type 2 diabetes.Methods: The study was performed in people with prediabetes (n = 2062; control:n = 1031; intervention:n = 1031) defined by HbA1c≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%). Participants were recruited from public and private sector organisations in India (men and women aged 35–55 years) and by the National Health Service (NHS) Health Checks programme in the UK (aged 40–74 years without pre-existing diabetes, cardiovascular disease or kidney disease). Allocation to the study groups was performed using a computer-generated sequence (1:1) in India and by stratified randomisation in permuted blocks in the UK. Investigators in both countries remained blinded throughout the study period. All participants received advice on a healthy lifestyle at baseline. The intervention group in addition received supportive text messages using mobile phone SMS messages 2–3 times per week. Participants were assessed at baseline and at 6, 12 and 24 months. The primary outcome was conversion to type 2 diabetes and secondary outcomes included anthropometry, biochemistry, dietary and physical activity changes, blood pressure and quality of life.Results: At the 2 year follow-up (n = 2062; control:n = 1031; intervention:n = 1031), in the intention-to-treat population the HR for development of type 2 diabetes calculated using a discrete-time proportional hazards model was 0.89 (95% CI 0.74, 1.07;p = 0.22). There were no significant differences in the secondary outcomes.Conclusions/interpretation: This trial in two countries with varied ethnic and cultural backgrounds showed no significant reduction in the progression to diabetes in 2 years by lifestyle modification using SMS messaging.Trial registration: The primary study was registered onwww.ClinicalTrials.gov(India, NCT01570946; UK, NCT01795833).Funding: The study was funded jointly by the Indian Council for Medical Research and the UK Medical Research Council.

9 December 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
EKE. Kousta
E. Kousta
ZEZoe A. Efstathiadou
Zoe A. Efstathiadou
NLN. J. Lawrence
N. J. Lawrence
JJJ. A. R. Jeffs
J. A. R. Jeffs
IGI. F. Godsland
I. F. Godsland
DJD. G. Johnston
D. G. Johnston

29 April 2016 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
PAPanagiotis Anagnostis
Panagiotis Anagnostis
JSJohn C. Stevenson
John C. Stevenson
DCDavid Crook
David Crook
DJDesmond G. Johnston
Desmond G. Johnston
IGIan F. Godsland
Ian F. Godsland
Summary: Objective: To undertake a comprehensive evaluation of apolipoprotein risk markers for cardiovascular disease (CVD) according to gender, age and menopausal status.Design: Cross‐sectional analysis of independent associations of gender, age and menopause with serum apolipoproteins.Participants: Apparently healthy Caucasian premenopausal (n = 109) and postmenopausal (n = 252) women not taking oral contraceptives or hormone replacement, and Caucasian men (n = 307).Measurements: Serum apolipoprotein (apo) B, A‐I and A‐II concentrations were measured, plus serum total cholesterol, low‐density and high‐density lipoprotein cholesterol (LDL‐C and HDL‐C, respectively), triglycerides, cholesterol in HDL subfractions and the apoB/apoA‐I, LDL‐C/apoB, HDL‐C/apoA‐I and HDL‐C/apoA‐II ratios. Analyses were undertaken with and without standardization for confounding characteristics and in 5‐year age ranges.Results: Overall, apoB concentrations were highest in men but in women rose with age and menopause to converge, in the age range of 50–55 years, with concentrations in men. The LDL‐C/apoB ratio was generally higher in women than in men. ApoA‐I concentrations were highest in postmenopausal women and lowest in men (standardized median (IQR) 144 (130, 158) vs 119 (108, 132) g/l, respectively, P < 0·001). ApoA‐II concentrations were also highest in postmenopausal women but were lowest in premenopausal women (40·3 (37·5, 44·5) vs 32·9 (30·5, 35·7) g/l, respectively, P < 0·001). Nevertheless, postmenopausal women had HDL‐C/apoA‐I and HDL‐C/apoA‐II ratios approaching the lowest ratios, which were seen in men.Conclusions: Consistent with adverse effects on CVD risk, male gender, ageing in women and menopause were associated with increased apoB concentrations, and menopause and male gender were associated with a decreased cholesterol content of HDL particles.